PlatformQ + ASGCT: Application and Consideration of Treatment Strategies for Relapsed/Refractory Multiple Myeloma

Watch on demand through March 20, 2025!

Standard-of-care frontline therapies do not have durable efficacy, with most patients eventually relapsing. In this setting, the number of therapeutic options for relapsed/refractory multiple myeloma (RRMM) has expanded leading to improved survival outcomes for people with MM. 

Join us to hear from Monique Hartley-Brown, MD, MMSc and Melissa Alsina, MD to discuss how clinicians can apply evidence-based guidelines to care, select the right therapy with the greatest clinical benefit for each patient, and differentiate among potentially practice-changing therapies. Panelists will also discuss how clinicians can remain familiar with the adverse events associated with newer therapy and key aspects of monitoring patients post therapy. 

Register for this CME program

Learning Objectives

After completing this activity, the participant should be better able to: 

  • Evaluate challenges to providing guideline-concordant care beyond the first-line 

  • Review new and emerging data and potentially practice-changing clinical trials in the relapsed-refractory setting 

  • Explain how to facilitate better alignment with patients/caregivers on goals of therapy  

Topics of Interest

  • Turning the tables for RRMM 

  • Survival in double- and triple-class refractory MM: Rationale for new options 

  • Approved and emerging agents with relevant clinical data 

  • Patient counseling and management of treatment-related adverse events (TRAEs) 

  • Targeted therapy for RRMM 

  • Patient preferences and treatment goals 

  • Real-world evidence on disconnects among patients/caregivers and providers 

Register for this CME program


Register for the ASGCT Policy Summit

September 23-24, 2024 | Washington, D.C.

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.